europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio’s 2022 Patient BioForum addresses the challenges of patients with unmet medical needs and calls for multi-stakeholder approach

02/12/2022
PRESS RELEASE

Brussels, 1 December 2022 

In recent years, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. A major hurdle to overcome is reaching a common understanding of unmet medical needs (hereafter - UMN) as stakeholders have different understandings of the concept based on different perceptions and expectations.

In response to the growing public debate about the definition of UMN, EuropaBio yesterday hosted 2022 Patient BioForum and invited multiple stakeholder groups to discuss and better understand patients’ with UMN experiences and facilitate progress towards a common understanding of the concept.

‘The Patient BioForum is a critical forum for patient-driven discussion and 2022 focussed on patients with unmet medical needs. The concept of UMN is particularly complex; rigid definition risks excluding patients from innovative treatments. Europe needs to put patients and their needs at the centre of the discussion and create a multi-stakeholder system ensuring that their voices are taken into account.’, said Claire Skentelbery, Director General of EuropaBio.

The discussions highlighted the importance of enhancing dialogue and collaboration between industry, patient organisations and policymakers in taking a more streamlined and harmonised approach to identifying UMNs.  This was confirmed by the results of the designated polls session;  69 % of event participants voted for a better dialogue with patients and other stakeholders.

The BioForum speakers and attendees agreed that Europe should caution against legislative intervention that will split the patient population and stifle innovation. Instead, the participants unanimously have asked to proceed with a multistakeholder approach and create a structure allowing stakeholders to exchange their views and identify a set of criteria of UNM.

The outcomes and recommendations from the event will be summarised into the report which will be published and publicly presented in January 2023.

Speakers: Joelle Khraiche, EuropaBio, Patient BioForum co-chair; Anca Toma, EPF, Patient BioForum co-chair; Tobias S. Hagedorn, Secretary of European Society for Phenylketonuria (ESPKU) and Managing Director of DIG PKU Germany; Pedro Franco, Director Europe for Global Regulatory & Scientific Policy at Merck and Chair of EuropaBio’s OMP WG. Moderator: Adrien Samson, Healthcare Biotechnology Manager, EuropaBio

EuropaBio’s 2022 Patient BioForum addresses the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies